Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce heart attacks.
Innate Pharma SA has entered into a collaboration with Sanofi to apply site-specific conjugation...
New research boosts hope that a highly anticipated, experimental class of cholesterol drugs can...
Sanofi said Thursday Brandicourt, 59, will start on April 2. He has been Bayer HealthCare's chairman and CEO since November 2013, and was also an executive for Pfizer Inc.
Sanofi SA acknowledged the job cuts in its Genzyme division Wednesday. The layoffs will largely effect facilities in Cambridge, with about 70 at the rare disease-focused Sanofi Genzyme Research and Development Center and 30 at a smaller cancer research center.
Boehringer Ingelheim and Sanofi announced today that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.
Catalent and Sanofi to Collaborate On Smartag™ Antibody-Drug Conjugate Technology With Sanofi’s Proprietary AntibodiesJanuary 15, 2015 8:07 am | News | Comments
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates (ADCs).
A paralegal recently fired by French drugmaker Sanofi has filed a whistleblower lawsuit, claiming she was discharged after protesting an alleged kickback scheme to increase U.S. sales of its insulin medicines.
Sanofi announced today that following a priority review, the FDA has approved Priftin in combination with isoniazid for a new indication for the treatment of latent tuberculosis infection in patients two years of age and older at high risk of progression to tuberculosis disease.
Sanofi sacked its CEO Wednesday following a board room rift over the handling of one of France's largest publicly traded companies. Christopher Viehbacher, the first non-Frenchman to lead Sanofi, was dismissed after six years running the company that traces its roots to the early 19th century.
Sanofi saw its stock price plunge today after it reported a slide in quarterly earnings and warned of pricing pressure on its blockbuster diabetes treatment in the U.S. Sanofi shares fell 8.4 percent to 76.39 euros, forfeiting gains in the run-up to the announcement.
The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.
The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as "breakbone fever," according to a large trial.
The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase its share of the diabetes treatment market, and the US-based company has three big weapons in its pharmaceutical arsenal, says an analyst with research and consulting firm GlobalData.
Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).
According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.
A former pharmaceutical executive has been sentenced to 16 months in prison for his role in an insider trading scheme. John Lazorchak was sentenced Tuesday in federal court in Newark, N.J.
Aastrom Biosciences announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million.
Two former pharmaceutical and medical technology firm executives have been sentenced for their involvement in an insider trading scheme.
Sanofi said today its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments.
Sanofi said Tuesday that its insulin U300 met its primary goals in a series of clinical trials, but some results were mixed. U300 is intended to be a longer-lasting version of Lantus that can be administered in lower doses. The company plans to file for marketing approval in the U.S. and European Union in the first half of 2014.
Sanofi said its net profit slumped by over a fifth in the third quarter as it continued to suffer the effects of overpaying for acquisitions and a painful restructuring. Sanofi SA said its net profit fell 21 percent to 1.21 billion euros ($1.66 billion) in the July to September quarter, from 1.54 billion euros a year earlier.
John Lazorchak, a former director of financial reporting at Summit-based Celgene Corp., and Mark Cupo, who held a similar position at Sanofi-Aventis, a France-based company with U.S. headquarters in Bridgewater, each pleaded guilty in federal court Monday to five counts of securities fraud.
Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.
The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.
Pozen has announced that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540. The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products. The companies...
Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.
Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.
- Page 1